ASSOCIATION BETWEEN THE POLYMORPHISM OF ANGIOTENSIN-CONVERTING ENZYME GENE AND INTERLEUKIN-1 BETA GENE AND THE RESPONSE TO ERYTHROPOIETIN THERAPY IN DIALYSIS PATIENTS WITH ANEMIA
Dzekova-Vidimliski P, Eftimovska-Otovikj N, Nikolov I G, Selim Gj, Rambabova-Bushljetik I, Pushevski V, Karanfilovski V, Matevska-Geshovska N, Dimovski A
*Corresponding Author: Assoc. Prof. Pavlina Dzekova-Vidimliski, MD, PhD, University Hospital for Nephrology, Mother Theresa str 17, 1000 Skopje, R. North Macedonia, Email address: pavlinadzekova@yahoo.com
page: 27
|
|
REFERENCES
1. Winearls CG, Oliver DO, Pippard MJ, Reid C, Down-
ing MR, Cotes PM. Effect of human erythropoietin
derived from recombinant DNA on the anaemia of
patients maintained by chronic haemodialysis. Lan-
cet. 1986; 2(8517):1175–1178.
2. Eschbach JW, Egrie JC, Downing MR, Browne JK,
Adamson JW. Correction of the anemia of end-stage
renal disease with recombinant human erythropoietin.
Results of a combined phase I and II clinical trial. N
Engl J Med. 1987 Jan 8;316(2):73-78.
3. Zins B, Drueke T, Zingraff J, Bererhi L, Kreis H,
Naret C, et al. Erythropoietin treatment in anaemic pa-
tients on haemodialysis. Lancet. 1986;2(8519):1329.
4. Besarab A, Bolton WK, Browne JK, Egrie JC, Nis-
senson AR, Okamoto DM, et al. The effects of normal
as compared with low hematocrit values in patients
with cardiac disease who are receiving hemodialysis
and detin. N Engl J Med. 1998; 339(9):584–590.
5. Locatelli F, Pisoni RL, Combe C, Bommer J, An-
dreucci VE, Piera L, et al. Anaemia in haemodialysis
patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes
and Practice Patterns Study (DOPPS). Nephrol Dial
Transplant. 2004; 19(1):121–132.
6. Wyatt CM, Drueke TB . Higher hemoglobin levels
and quality of life in patients with advanced chronic
kidney disease: no longer a moving target? Kid-
ney Int. 2016 May;89(5):971-973.
7. Okazaki M, Komatsu M, Kawaguchi H, Tsuchiya
K, Nitta K. Erythropoietin resistance index and the
all-cause mortality of chronic hemodialysis patients.
Blood Purif. 2014;37(2):106-112.
8. KDIGO clinical practice guideline for anemia in
chronic kidney disease. Chapter 3. Use of ESAs
and other agents to treat anemia in CKD. Kidney Int
Suppl. 2012; 2:299–310.
9. USRDS. 2013 Annual Data Report: Atlas of chronic
kidney disease and end-stage renal disease in the
United States, national institutes of health, ànd na-
tional institute of diabetes and digestive and kidney
diseases. MD: Bethesda; 2013.
10. Wong HS, Chang CM, Kao CC, Hsu YW, Liu
X, Chang WC, Wu MS, Chang WC. V-J combina-
tions of T-cell receptor predict responses to erythro-
poietin in end-stage renal disease patients. J Biomed
Sci. 2017 Jul 11;24(1):43.
11. Priyadarshi A, Shapiro JI. Erythropoietin resistance in
the treatment of the anemia of chronic renal failure.
Semin Dial 2006;19:273-278.
12. Sharples EJ, Varagunam M, Sinnott PJ, McCloskey
DJ, Raftery MJ, Yaqoob MM. The effect of proinflam-
matory cytokine gene and angiotensin-converting
enzyme polymorphism on erythropoietin require-
ments in patients on continuous ambulatory perito-
neal dialysis. Perit Dial Int 2006; 26:64-68.
13. Nand N, Deshmukh AR, Joshi S, Sachdeva
MP, Sakthivel. Role of ACE and IL-1β Gene Poly-
morphism in Erythropoeitin Hyporesponsive Patients
with Chronic Kidney Disease with Anemia. J Assoc
Physicians India. 2017 Feb;65(2):32-36.
14. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Cor-
vol P, Soubrier F. An insertion/deletion polymorphism
in the angiotensin I-converting enzyme gene account-
ing for half the variance of serum enzyme levels. J
Clin Invest 1990; 86: 1343-1346.
15. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT.
Angiotensin II stimulates proliferation of normal
early erythroid progenitors. J Clin Invest 1997;100:
2310-2314.
16. Kim YC, Mungunsukh O, Day RM. Erythropoietin
Regulation by Angiotensin II. Vitam Horm. 2017;
105:57-77.
17. Dinarello CA. Biologic basis for interleukin-1 in dis-
ease. Blood 1996;87: 2095-2147.
18. Jelkmann W. Proinflammatory cytokines lowering
erythropoietin production. J Interferon Cytokine Res
1998; 18:555-559.
19. Jeong KH, Lee TW, Ihm CG, Lee SH, Moon JY.
Polymorphism in two genes, IL-1B and ACE, are
associated with erythropoietin resistance in Korean
patients on maintenance hemodialysis. Exp Mol Med.
2008 Apr 30;40(2):161-166
20. Berns JS. Interpretation of the Kidney Disease: Im-
proving Global Outcomes guidelines for iron therapy:
commentary and emerging evidence. Clin Kidney
J. 2017 Dec;10(Suppl 1):i3-i8.
21. KDIGO 2017 Clinical Practice Guideline Update for
the Diagnosis, Evaluation, Prevention, and Treatment
of Chronic Kidney Disease–Mineral and Bone Disor-
der (CKD-MBD). Kidney International Supplements
2017; 7: 1–59.
22. Varagunam M, McCloskey DJ, Sinnott PJ, Raftery
MJ, Yaqoob MM. Angiotensin-converting enzyme
gene polymorphism and erythropoietin requirement.
Perit Dial Int 2003; 23:111-115.
23. Santos EJF, Hortegal EV, Serra HO, Lages JS, Salga-
do-Filho N, Dos Santos AM. Epoetin alfa resistance
in hemodialysis patients with chronic kidney disease:
a longitudinal study. Braz J Med Biol Res. 2018;
51(7):e7288.
24. Kaneko S, Hirai K, Morino J, Minato S, Yanai K,
Mutsuyoshi Y, Ishii H, Matsuyama M, Kitano T,
Shindo M, Aomatsu A, Miyazawa H, Ueda Y, Ito
K, Ookawara S, Morishita Y. Association between
carnitine deficiency and the erythropoietin resistance
index in patients undergoing peritoneal dialysis: a
cross-sectional observational study. Ren Fail. 2020
Nov;42(1):146-153.
25. Wu HHL, Chinnadurai R. Erythropoietin-Stimulating
Agent Hyporesponsiveness in Patients Living with
Chronic Kidney Disease. Kidney Dis (Basel). 2022
Jan 14; 8(2):103-114.
26. Radić J, Bašić-Jukić N, Vujičić B, Klarić D, Radulović
G, Jakić M, et al. Anemia Is Correlated with Malnutri-
tion and Inflammation in Croatian Peritoneal Dialysis
Patients: A Multicenter Nationwide Study. Perit Dial
Int. 2017 Jul-Aug;37(4):472-475.
27. Weir MR. Managing Anemia across the Stages of
Kidney Disease in Those Hyporesponsive to Eryth-
ropoiesis-Stimulating Agents. Am J Nephrol. 2021;
52(6):450-466.
28. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Com-
bined high serum ferritin and low iron saturation in
hemodialysis patients: the role of inflammation. Clin
J Am Soc Nephrol. 2008 Nov;3(6):1691-1701.
29. Karaboyas A, Morgenstern H, Fleischer NL, Van-
holder RC, Dhalwani NN, Schaeffner E, et al. Inflam-
mation and erythropoiesis-stimulating agent response
in hemodialysis patients: a Self-matched Longitudinal
Study of anemia management in the dialysis out-
comes and Practice Patterns Study (DOPPS). Kidney
Med. 2020;2:286–296
30. Kiss Z, Ambrus C, Kulcsár I, Szegedi J, Kiss I.
ACEGENE-BB_HU workgroup; ACEGENE-BB HU
workgroup. Effect of angiotensin-converting enzyme
gene insertion/deletion polymorphism and angioten-
sin-converting enzyme inhibition on erythropoiesis
in patients on haemodialysis. J Renin Angiotensin
Aldosterone Syst. 2015 Dec;16(4):1021-1027.
31. Hatano M, Yoshida T, Mimuro T, Kimata N, Tsuchiya
K, Sanaka T, Nihei H. The effects of ACE inhibitor
treatment and ACE gene polymorphism on erythro-
poiesis in chronic hemodialysis patients. Nihon Jinzo
Gakkai Shi. 2000 Oct; 42(8):632-639.
32. Al-Radeef, M. Y., Fawzi, H. A., & Allawi, A. A. ACE
gene polymorphism and its association with serum
erythropoietin and hemoglobin in Iraqi hemodialy-
sis patients. The Application of Clinical Genetics.
2019; 12: 107-112.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
